PharVision Advisers’s Riskified RSKD Stock Holding History

PharVision Advisers’s Portfolio RSKD Stock Details RSKD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,863	Closed	-$69.6K	–	964
2025 Q3	$69.6K	Buy	+14,863	New	+$73.2K	0.04%	640

Other funds holding RSKD

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PharVision Advisers's RSKD Position: Q4 2025 in Review

PharVision Advisers sold out of Riskified (RSKD) in Q4 2025, closing a stake of 14,863 shares — an estimated $69.6K sold.

PharVision Advisers first reported a position in RSKD in Q3 2025 and held it in 1 quarter. The position peaked at $69.6K in Q3 2025. 107 funds tracked by Wall St. Rank hold RSKD as of Q4 2025.

PharVision Advisers reported no remaining Riskified position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 14,863 Riskified shares in Q4 2025, an estimated $69.6K.
PharVision Advisers first reported a position in Riskified in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Riskified position peaked at $69.6K in Q3 2025.
107 funds tracked by Wall St. Rank held Riskified as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.